918643-51-3

Basic information

• Product Name: 1-ethyl-4-iodo-1H-iMidazole
• Synonyms: 1-ethyl-4-iodo-1H-iMidazole;1H-Imidazole, 1-ethyl-4-iodo-
• CAS NO: 918643-51-3
• Molecular Formula: C₅H₇IN₂
• Molecular Weight: 222.02695
• Mol File: 918643-51-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-ethyl-4-iodo-1H-iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ethyl-4-iodo-1H-iMidazole(918643-51-3)
• EPA Substance Registry System: 1-ethyl-4-iodo-1H-iMidazole(918643-51-3)

Safety Data

• Hazardous Substances Data: 918643-51-3(Hazardous Substances Data)

Usage

Class

Imidazole derivative

Structure

Five-membered ring with two non-adjacent nitrogen atoms

Substituents

Ethyl group and iodine atom attached to the imidazole ring

Applications

Chemical and pharmaceutical industries

Usage

Building block for synthesis of other compounds, reagent in chemical reactions

Potential

Biological activity, interest in medicinal chemistry, drug development

Specific properties

Depend on interactions with other molecules and context of utilization

Upstream product

• 74-96-4 ethyl bromide 
• 71759-89-2 4-iodoimidazole 

Relevant articles and documents

PYRAZOLE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS

The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human deh

Original 2-(3-Alkoxy-1 H -pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)

Following our discovery of human dihydroorotate dehydrogenase (DHODH) inhibition by 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as well as 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyridine, we describe here the syntheses and evaluation of an array of azine-bearing analogues. As in our previous report, the structure-activity study of this series of human DHODH inhibitors was based on a phenotypic assay measuring measles virus replication. Among other inhibitors, this round of syntheses and biological evaluation iteration led to the highly active 5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-3-fluoropyridine. Inhibition of DHODH by this compound was confirmed in an array of in vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular growth. This molecule was found to be more active than the known inhibitors of DHODH, brequinar and teriflunomide, thus opening perspectives for its use as a tool or for the design of an original series of immunosuppressive agent. Moreover, because other series of inhibitors of human DHODH have been found to also affect Plasmodium falciparum DHODH, all the compounds were assayed for their effect on P. falciparum growth. However, the modest in vitro inhibition solely observed for two compounds did not correlate with their inhibition of P. falciparum DHODH.